Atomoxetine May Aid Memory in Older Women
By David Douglas
本文翻譯自[Medscape] http://www.medscape.com/viewarticle/737791?src=rss
本文同步發表於批踢踢藥師版
NEW YORK (Reuters Health) Feb 22 - Atomoxetine may improve subjective
attention and reduce memory difficulties in perimenopausal and postmenopausal
women, researchers report in a February 2nd online paper in Menopause.
根據 The Journal of Menopause 二月份發表的研究指出：更年期與停經後的婦女使
用atomoxetin，可能可以增進注意力的集中和降低記憶力下降的問題。
Dr. C. Neill Epperson told Reuters Health by email that "subjective declines
in memory, focus and organization are common in mid-life women. We believe
that the results of our small randomized clinical trial provide proof-of-concept
that atomoxetine may improve subjective memory, attention and concentration."
Dr. C. Neil Epperson表示：「記憶力障礙的問題常見於中年婦女，我們相信此次的
小型隨機分配的臨床試驗之結果，將為atomoxetin用於提升記憶力、注意力和專注力
的角色，提供一個觀念性驗證 (proof-of-concept, 請指點要怎麼翻比較好!!) 的佐證。」
"These findings will need to be confirmed in a larger randomized clinical trial
before clinical recommendations can be made. However, women who are
concerned about memory changes in mid-life may wish to discuss the results of
this study with their doctor," he added.
Dr. C.N. Epperson接著說：「此次實驗的結果仍須要其他更大型的臨床試驗以進行確
認（sample size的確是不夠大...） 。然而，關心本身記憶衰退問題的中年女性們，仍
可能會希望與其醫師討論此實驗的結果。」
Dr. Epperson of the University of Pennsylvania School of Medicine, Philadelphia,
and colleagues sought to determine the effect of the drug in 16 women with
memory complaints but no history of attention-deficit/hyperactivity disorder
(ADHD) or other psychiatric disorders.
菲律賓Pennsylvania大學醫學院的Dr. Epperson收納了16位有記憶問題困擾，且沒有
任何"注意力不集中/過動症(ADHD)"病史或其他精神疾病病史的女性，以評估藥物對記憶
的效果。
They were enrolled in a double-blind, placebo-controlled crossover study of
atomoxetine 80 mg/day during two 6-week treatment periods separated by a
4-week washout period.
本實驗設計為：雙盲交叉試驗(placebo vs. atomoxetine 60 mg/day)
共各有六週的投藥 or 安慰劑的treatment periods
中間的washout period為四個禮拜
The Brown Attention Deficit Disorder Scale (BADDS) was used to systematically
elicit self-report of perceived cognitive difficulties in executive function.
This 40-item measure asks respondents to use a scale of 0-3 (where 0 = "no
problem or never" and 3 = "kind of a big problem or almost every day"). Mean
baseline score was 37.9 in all participants and 42.3 in the 12 who completed
both arms of the study.
受試者皆以BADDS進行自我認知評量。這份量表有40項目，每個項目依受試者主觀判
定程度填寫 0-3 分 ( 0 = 沒問題/從不 ; 3 = 噢這是個大問題~/這每天都在發生)。
所有受試者的平均基準受測質為37.9分，而在完成整個試驗的12位受試者的基準受測
值則為42.3分。
BADDS scores fell to 25.5 with atomoxetine, a significant difference (p = 0.009).
Although scores decreased to 30.1 under placebo, the difference from baseline
wasn't significant (p= 0.2).
實驗結果：
BADDS of Baseline BADDS of Post-treatment p-value
Atomoxetine 42.3 25.5 0.009*
Placebo 42.3 30.1 0.2
There was no observable effect on levels of depression or anxiety with
atomoxetine.
在藥物不良反應方面，本次試驗並沒有發現在atomoxetine的受試者中，有發生顯著
的憂鬱或焦慮的副作用。
"Such research could be useful to test whether self-report elicited with ADHD
rating scales may capture midlife-onset cognitive impairments of women that
may not be captured adequately by neuropsychological tests," say the investigators.
試驗執行者表示：「本次試驗發現，對於一些在神經精神科學檢測上無法測量，但利用自
我問卷評估方式，卻能有效鑑測中年認知功能失常之女性患者，一個有效的評估方式。」
這個效度與信度 可能需要其他實驗設計來佐證...
They also suggest that higher doses of atomoxetine and "studies using other
medications approved for treatment of ADHD in adults might also be useful" in
such patients.
作者亦提到：「更高劑量的atomoxetine可能是有效的。」
「其他被核准用於治療ADHD的藥物，對此類病患可能也是有效的。」
The study was funded by an investigator-initiated grant from Eli Lilly &
Company and in part by the National Institute of Mental Health.
本試驗由Eli Lill藥廠和國家精神健康研究機構贊助執行
Menopause. Posted online February 2, 2011
Abstrate Link: http://0rz.tw/ULk9X
感冒吃藥了 昏昏沉沉暫時睡不著
就獻醜翻了翻這篇
如有錯誤或不足 請大家不吝指教 謝謝大家
留言列表
